177 related articles for article (PubMed ID: 26919736)
1. Development of potent and long-acting HIV-1 fusion inhibitors.
Chong H; Wu X; Su Y; He Y
AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736
[TBL] [Abstract][Full Text] [Related]
2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
3. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
4. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
Chong H; Qiu Z; Su Y; Yang L; He Y
AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
[TBL] [Abstract][Full Text] [Related]
5. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
7. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
8. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
9. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
10. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
[TBL] [Abstract][Full Text] [Related]
11. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
[TBL] [Abstract][Full Text] [Related]
12. A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.
Su S; Rasquinha G; Du L; Wang Q; Xu W; Li W; Lu L; Jiang S
Molecules; 2019 Mar; 24(6):. PubMed ID: 30901967
[TBL] [Abstract][Full Text] [Related]
13. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
14. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
[TBL] [Abstract][Full Text] [Related]
17. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
Su S; Ma Z; Hua C; Li W; Lu L; Jiang S
Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603
[TBL] [Abstract][Full Text] [Related]
18. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
He Y
Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
[TBL] [Abstract][Full Text] [Related]
19. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
[TBL] [Abstract][Full Text] [Related]
20. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
